All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Adjuvant Olaparib Significantly Improves OS in BRCA+, High-Risk Early Breast Cancer

March 17th 2022

At a median follow-up of 3.5 years, adjuvant olaparib significantly improved overall survival vs placebo in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who received prior chemotherapy before or after surgery.

Toripalimab/Chemo Combo Provides Significant Survival Benefit in NSCLC Without EGFR/ALK Mutations

March 16th 2022

The addition of toripalimab to chemotherapy resulted in improved progression-free survival and overall survival vs chemotherapy alone in patients with treatment-naïve advanced non–small cell lung cancer without EGFR or ALK mutations.

Guardant360 CDx Approved in Japan for Utilization in Advanced Solid Tumors

March 16th 2022

The Ministry of Health, Labour, and Welfare has approved Guardant360 CDx to perform comprehensive genomic profiling in patients with advanced solid cancers.

Top 8 Trials From 2021 in Breast Cancer

March 16th 2022

Leading oncologists in breast cancer share their perspectives on the biggest abstracts that were presented throughout 2021 .

Precision Medicine Takes Hold of Prostate Cancer Management

March 16th 2022

The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.

Roy S. Herbst, MD, PhD, Honored by IASLC

March 16th 2022

Roy S. Herbst, MD, PhD, was honored by the International Association for the Study of Lung Cancer in recognition for his years of dedication and invaluable service to the organization and the lung cancer community.

Navigating Frontline RCC Treatment Paths Relies on Risk Stratification

March 16th 2022

Primo Nery Lara Jr, MD, provides an overview of the treatment landscape for patients with metastatic renal cell carcinoma.

Investigators Look Beyond Immune Checkpoint Inhibitors to Chase Moving Targets in Prostate Cancer

March 16th 2022

Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.

Relatlimab/Nivolumab Combo Continues to Impress in Previously Untreated Metastatic or Unresectable Melanoma

March 15th 2022

The fixed-dose combination of relatlimab and nivolumab continued to demonstrate a consistent progression-free survival benefit, showcased a clinically meaningful improvement in overall survival, and elicited a higher objective response rate than nivolumab alone in previously untreated patients with metastatic or unresectable melanoma.

Allarity Therapeutics Requests Type C Meeting With FDA to Discuss Dovitinib in Third-Line RCC

March 15th 2022

Allarity Therapeutics, Inc. has filed a formal request with the FDA to hold a Type C meeting where they can discuss possible clinical paths to support the approval of dovitinib in renal cell carcinoma, as well as its DRP-Dovitinib companion diagnostic.

Phase 3 KEYLYNK-010 Trial Examining Pembrolizumab/Olaparib in mCRPC to Stop for Futility

March 15th 2022

The phase 3 KEYLYNK-001 trial evaluating the combination of pembrolizumab and olaparib in patients with metastatic castration-resistant prostate cancer who progressed following chemotherapy and either abiraterone acetate or enzalutamide will be discontinued for futility.

ADT-Based Combinations Have Become Standard Therapy for Metastatic Castration-Sensitive Prostate Cancer

March 15th 2022

Overwhelming evidence has pointed to the use of androgen deprivation therapy in combination with 1 or 2 other agents as the standard of care for patients with metastatic castration-sensitive prostate cancer.

Frontline Cabozantinib/Atezolizumab Does Not Improve OS Over Sorafenib in Advanced HCC

March 15th 2022

The combination of cabozantinib and atezolizumab was not found to result in an improvement nor a detriment in overall survival vs sorafenib when used in previously untreated patients with advanced hepatocellular carcinoma, according to data from the phase 3 COSMIC-312 trial.

NCCN Lists Duvelisib in Updated Clinical Practice Guidelines

March 15th 2022

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology has been updated to include duvelisib as a category 2A designated option for second-line and subsequent treatment of patients with relapsed/refractory peripheral T-cell lymphoma.

ESR1 Data Fuel Novel Breast Cancer Strategies

March 15th 2022

Mutations on the ESR1 gene, which encodes the estrogen receptor, have emerged as an important driver of resistance to endocrine therapies, which form the backbone of treatment for patients with ER-positive, HER2-negative breast cancer.

Neoadjuvant Chemotherapy Benefit Retains Stronghold for Patients With MIBC, UTUC

March 15th 2022

Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.

Amcenestrant Misses PFS End Point in ER+/HER2– Advanced or Metastatic Breast Cancer

March 14th 2022

Amcenestrant did not improve progression-free survival per independent central review vs physician’s choice of endocrine treatment in select patients with locally advanced or metastatic, estrogen receptor–positive, HER2-negative breast cancer, missing the primary end point of the phase 2 AMEERA-3 trial.

Frontline Bempegaldesleukin/Nivolumab Combo Misses Primary End Points in Unresectable or Metastatic Melanoma

March 14th 2022

The addition of bempegaldesleukin to nivolumab did not significantly improve progression-free survival, objective response rate, or overall survival vs nivolumab alone in the frontline treatment of patients with unresectable or metastatic melanoma, missing the primary end points of the phase 3 PIVOT IO-001 trial.

FDA Approves Companion Diagnostic for Olaparib in Early Breast Cancer

March 14th 2022

The FDA has approved the BRACAnalysis CDx assay for use as a companion diagnostic to select patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who may derive clinical benefit from treatment with olaparib.

Gynecologic Malignancies Management Makes Significant Strides With ADCs, PARP Inhibitors, and Checkpoint Blockade

March 14th 2022

Alexander Babatunde Olawaiye, MD, discusses frontline and second-line maintenance in ovarian cancer, the role of surgery in platinum-sensitive disease, and updates in cervical and endometrial cancers.